Table 1 Description of liver dysfunction between survivors and non-survivors among included studies
From: A meta-analysis of the impact of COVID-19 on liver dysfunction
Study, year | Setting | Country | Sample (dead/alive) | Age (dead/alive) | Chronic liver disease (dead/alive) | ALT (dead/alive) | AST (dead/alive) | Female gender | NOS |
|---|---|---|---|---|---|---|---|---|---|
Yang et al. [7], 2020 | ICU | China | 32/20 | 64.6 (11.2)/51.9 (12.9) | NA | NA | NA | 11/6 | 7 |
Wang et al. [13], 2020 | Isolation ward | China | 65/274 | 76 (70–83)/68 (64–74) | 1/1 | 24 (19–49)/28 (17–43) | 43 (30–68)/29 (22–43) | 26/147 | 7 |
Chen N et al. [14], 2020 | Isolation ward | China | 113/161 | 68.0(62.0–77.0)/51.0(37.0–66.0) | 5/6 (HBsAg +) | 28.0 (18.0–47.0)/ 20.0 (14.8–32.0) | 45.0 (31.0–67.0)/ 25.0 (20.0–33.3) | 30/73 | 8 |
Zhou et al. [16] 2020 | Isolation ward | China | 54/135 | 69·0 (63·0–76·0)/52·0 (45·0–58·0) | NA | 40.0 (24.0–51.0)/27.0 (15.0–40.0) | NA | 16/56 | 7 |
Du et al. [15], 2020 | Isolation ward | China | 21/158 | 70.2(7.7)/56.0(13.5) | 2/2 | 27.0 (20.0‒37.0)/22.0 (14.0‒40.5) | 40.0 (27.0‒61.5)/27.5 (19.0‒42.0) | 11/71 | 7 |